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Introduction
Early menopause has been associated with 
several adverse health outcomes including 
loss of bone mineral density (Gallagher 2007) 
and cardiovascular disease morbidity (Atsma 
et al. 2006; Cui et al. 2006) and mortality 
(Ossewaarde et al. 2005; van der Schouw 
et al. 1996). Indeed, cardiovascular disease is 
still the most common cause of death among 
women worldwide (Mathers et al. 2009). 
Therefore, mitigation of population expo-
sures to risk factors for early age at meno-
pause could yield significant benefits in terms 
of reducing chronic disease morbidity and 
  mortality in postmenopausal life.
Adverse female reproductive function 
effects of lead exposure have been reported in 
both animal/in vitro and human epidemio-
logical studies. Although experimental studies 
have usually used high exposures and/or 
exposure routes not reflective of human ones, 
they have found lead-associated disrup-
tion of gonadal function and reproductive 
hormone production with prenatal as well 
as later life exposures (Nampoothiri and 
Gupta 2006; Pillai et al. 2010) and poten-
tial impairment of hypothalamic–pituitary–
gonadal (HPG) signaling (McGivern et al. 
1991). Epidemiological studies have found 
associations between lead exposure and vari-
ous reproductive end points, including dis-
ruption of reproductive hormones among 
peripubertal girls (Gollenberg et al. 2010), 
later puberty (Naicker et al. 2010; Selevan 
et al. 2003), reduced fertility (Chang et al. 
2006; Snijder et al. 2012), and menstrual 
abnormalities and spontaneous abortion in 
an occupational group (Tang and Zhu 2003). 
For example, among 8- to 18-year-old girls 
participating in the third National Health and 
Nutrition Examination Survey (NHANES), 
modestly higher blood lead levels (3 μg/dL vs. 
1 μg/dL) were associated with later pubertal 
development (Selevan et al. 2003). Among 
battery plant and capacitor factory workers, 
52 lead-exposed female workers were found to 
have a higher prevalence of menstrual abnor-
malities, including polymenorrhea or hyper-
menorrhea and spontaneous abortion, than 
62 controls randomly sampled from plant 
workers in non-lead-production departments 
(Tang and Zhu 2003).
With respect to lead and menopause, most 
research, including an earlier study in the 
Nurses’ Health Study cohort (Korrick et al. 
2002), has focused on the effects of meno-
pause on blood lead levels (Garrido Latorre 
et al. 2003; Jackson et al. 2010; Nash et al. 
2004; Potula and Kaye 2006; Vahter et al. 
2004). Release of lead from bone to blood 
as a consequence of increased bone turnover 
following menopause has been proposed as a 
mechanism that may explain cross-sectional 
associations between menopause and blood 
lead levels. However, to our knowledge, only 
two prior studies have attempted to examine 
the association between lead exposure and age 
at menopause (Mendola et al. 2013; Popovic 
et al. 2005). One was a small study among for-
mer smelter workers who were found to have 
earlier menopause compared with community-
based controls, but selection bias or uncon-
trolled confounding by other occupational 
exposures could have affected the findings. 
The second study was a cross-sectional analysis 
of 1,782 women in NHANES among whom 
increased odds of natural menopause was seen 
with higher blood lead levels (Mendola et al. 
2013). However, given the cross-sectional 
analysis and roughly 30-day half-life of blood 
lead, whether lead caused the earlier meno-
pause or earlier menopause caused the higher 
blood lead is difficult to determine. We are 
not aware of any studies that have explored the 
association between a biomarker of cumulative 
lead exposure and age at menopause at lower-
level, nonoccupational exposures   typically 
experienced by women.
To explore the association between lead 
exposure and age at menopause, we measured 
lead concentration in bone—a biomarker 
of cumulative lead exposure—among older 
women participants in the Nurses’ Health 
Study (NHS).
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Background: Early menopause has been associated with many adverse health outcomes,   including 
increased risk of cardiovascular disease morbidity and mortality. Lead has been found to be 
adversely associated with female reproductive function, but whether exposures experienced by the 
general population are associated with altered age at menopause has not been explored.
oBjective: Our goal was to assess the association between cumulative lead exposure and age at 
natural menopause.
Methods: Self-reported menopausal status and bone lead concentration measured with K-shell 
X-ray fluorescence—a biomarker of cumulative lead exposure—were obtained from 434 women 
participants in the Nurses’ Health Study.
results: The mean (± SD) age at natural menopause was 50.8 ± 3.6 years. Higher tibia lead level 
was associated with younger age at menopause. In adjusted analyses, the average age of menopause 
for women in the highest tertile of tibia lead was 1.21 years younger (95% CI: –2.08, –0.35) than 
for women in the lowest tertile (p-trend = 0.006). Although the number of cases was small (n = 23), 
the odds ratio for early menopause (< 45 years of age) was 5.30 (95% CI: 1.42, 19.78) for women 
in the highest tertile of tibia lead compared with those in the lowest tertile (p-trend = 0.006). There 
was no association between patella or blood lead and age at menopause.
conclusions: Our results support an association between low-level cumulative lead exposure and 
an earlier age at menopause. These data suggest that low-level lead exposure may contribute to 
menopause-related health outcomes in older women through effects on age at menopause.
citation: Eum KD, Weisskopf MG, Nie LH, Hu H, Korrick SA. 2014. Cumulative lead 
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Methods
Study population. The NHS is an ongoing 
prospective cohort study initiated in 1976 
when 121,700 female registered nurses, 30 to 
55 years of age and living in 11 U.S. states, 
completed a questionnaire on their medical 
history and health-related behaviors (Colditz 
et al. 1997). The study was designed to assess 
the relation of diet, lifestyle, and other factors 
with women’s risk of a wide range of chronic 
diseases. Since its inception, participants have 
completed mailed questionnaires every 2 years 
with response rates of approximately 90%.
The NHS participants in our analyses 
consisted of a subgroup living in the greater 
Boston area and assessed in two sequential 
studies of lead exposure and chronic dis-
ease risk in women. In both studies, lead in 
blood as well as in tibia and patella bone was 
measured. The first NHS subgroup consisted 
of 301 women participating in a nested case–
control study of lead exposure and hyperten-
sion (Korrick et al. 1999). For that study, we 
invited women to take part if they lived in the 
greater Boston, Massachusetts, metropolitan 
area; did not have a history of a major, chronic 
disease; and were not obese [body mass index 
(BMI) ≥ 29 kg/m2]. Women who had no his-
tory of major, chronic disease (no reported 
diagnosis of hypertension, cardiovascular 
disease, renal disease, diabetes, or malignancies) 
were invited to participate as controls from 
1990 through 1994, and women who first 
reported a diagnosis of hypertension between 
1990 and 1994 were invited to participate as 
cases. Controls were frequency matched to 
cases by 5-year age groups. In total, between 
1993 and 1995, 301 NHS participants (101 
hypertension cases and 200 controls) agreed 
to participate and underwent study evaluation, 
including measurement of their lead levels.
The women in the second Boston-area 
NHS subgroup were originally recruited for 
a cohort study of lead exposure and bone 
density (Weuve et al. 2009). Similar eligibility 
criteria used for controls in the hypertension 
study applied here, with participants having 
no history of chronic diseases (no reported 
diagnosis of hypertension, cardiovascular 
disease, renal disease, diabetes, or malignan-
cies) invited to participate from 2001 through 
2004. In total, 320 NHS participants com-
pleted the bone density study evaluations 
that included lead measurements. The two 
substudies were nonoverlapping, with a 
combined total of 621 unique participants.
We used lead exposure measures, ques-
tionnaire, and health information collected 
in these two Boston area substudies and in 
the biennial main NHS questionnaires for the 
current analysis.
Age at menopause. Menopausal status 
was determined on the first NHS ques-
tionnaire in 1976 and then again on each 
biennial questionnaire by asking whether the 
participants’ menstrual periods had ceased 
permanently and, if so, at what age and for 
what reason (natural or surgical). Of the 621 
women with lead measurements, 610 had 
data on age at menopause. Of those women, 
449 reported natural menopause, 154 surgical 
menopause, and seven were missing data on 
menopause type. Among the 449 with natu-
ral menopause, we excluded 15 with missing 
covariate data, leaving 434 for the current 
analysis. Thirty-three women reported meno-
pause having occurred between 1957 and 
1976, before the first NHS questionnaire. 
The remaining 401 women underwent meno-
pause between 1976 and 2003. We defined 
early menopause as natural menopause occur-
ring before 45 years of age (Gallagher 2007).
Lead exposure assessment. Participants 
visited the outpatient General Clinical 
Research Center (GCRC) of the Brigham and 
Women’s Hospital for measurement of lead 
content in their bone by K-shell X-ray fluo-
rescence (KXRF), a noninvasive technique 
for measuring skeletal lead content that can 
measure very low lead concentrations (Aro 
et al. 2000; Nie et al. 2008). The KXRF 
instrument provides an estimate of bone lead 
levels normalized to bone mineral content 
(expressed as micrograms of lead per gram 
of bone mineral). Negative estimates of bone 
lead concentrations may occur for lead values 
close to zero. In epidemiologic studies, use of 
all point estimates, including negative values, 
has less bias and greater analytic efficiency 
than imposing a minimum detectable limit 
(MDL) and recoding data below the MDL 
(Kim et al. 1995).
Bone lead measurements were made at 
each woman’s mid-tibial shaft and patella. 
These sites are targets for bone lead research 
because the tibia consists mainly of cortical 
bone, and the patella of trabecular bone. The 
estimated half-lives of lead in cortical and tra-
becular bone in a cohort of older men were on 
the order of decades and several years, respec-
tively (Wilker et al. 2011). However, a faster 
rate of decrease in bone mineral density with 
older age among women compared with men, 
primarily related to postmenopausal changes 
in bone physiology (Riggs et al. 1982), likely 
makes these half-lives shorter in women.
When we began measuring the women’s 
bone lead, we used an instrument developed 
by ABIOMED (Danvers, MA). A technical 
description and validity specifications of this 
instrument have been published elsewhere 
(Aro et al. 2000). In 1999, we replaced our 
prototype ABIOMED instrument with an 
upgraded instrument designed to be more 
precise, through changes in the cadmium 
radiation source, adjustments to the geometry 
of the measurement procedure, and upgrades 
in both the system’s software and specific 
hardware components (Aro et al. 1994). 
Intercalibration data from persons who were 
measured on both instruments demonstrated 
a linear relationship between the two mea-
surements with a slope of 0.87. Using this 
correction factor, we are able to combine data 
from our prototype and upgraded KXRF 
machines (Nie et al. 2008). To reduce the 
impact of any additional scaling differences in 
these readings on our epidemiologic analyses, 
we included a term for lead substudy in our 
regression models, which effectively adjusts 
for instrument, because women from the 
hypertension substudy were assessed on the 
ABIOMED instrument (Korrick et al. 1999), 
and women from the bone density substudy 
were assessed on the upgraded instrument 
(Weuve et al. 2009).
Whole blood samples were collected in 
trace-metal-free tubes (with EDTA), and lead 
levels were analyzed using graphite furnace 
atomic absorption with Zeeman background-
correction (ESA Laboratories, Chelmsford, 
MA). After every 20 samples, the instrument 
was calibrated with National Institute of 
Standards and Technology (NIST) Standard 
Reference Material (SRM) 955a, lead in blood 
(NIST, Gaithersburg, MD). To test internal 
reliability, 10% of samples were run in dupli-
cate; at least 10% of the samples were controls 
and 10% were blanks. To test external valid-
ity, reference samples from the U.S. Centers 
for Disease Control and Prevention (Atlanta, 
GA) were measured. Coefficients of variation 
ranged from 8% for lead concentrations of 
10–30 μg/dL to 1% for higher concentrations. 
The limit of detection (LOD) was 1 μg/dL; 
values below the LOD were assigned a value 
of 0.71 μg/dL (1 μg/dL divided by the square 
root of 2).
Statistical analysis. We used ordinary 
least-squares linear regression to analyze age 
at menopause as a continuous dependent 
variable. We used logistic regression to esti-
mate odds ratios (ORs) and 95% CIs for 
early menopause. We conducted analyses 
for blood, patella and tibia bone lead bio-
markers (separately) categorized into tertiles 
for models for age at menopause as a con-
tinuous variable and early menopause. For 
trend analyses, we fit models using a single 
continuous lead biomarker term created by 
assigning to each woman the median value of 
her lead biomarker tertile, which reduces the 
influence of extreme values. In addition, we 
also report results of trend analyses based on 
categorizing lead in quintiles. Analyses were 
adjusted for age at menarche (years), year of 
birth, substudy group, age at bone lead mea-
surement (years), age at bone lead measure-
ment squared, months of oral contraceptive 
use, parity (0, 1–2, 3, ≥ 4), and pack-years of 
smoking assessed at the time of menopause. 
In sensitivity analyses, we further adjusted Cumulative lead exposure and age at menopause
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for alcohol consumption (< 1, 1–5, 5–10, 
≥ 10 g/day) and BMI (< 20, 20–25, ≥ 25) 
at the time of menopause because these are 
not consistently associated with menopause. 
Because age at menopause may affect the use 
of postmenopausal hormone replacement 
therapy (HRT), we did not adjust for HRT 
in our primary analyses. However, we did sec-
ondary sensitivity analyses adjusted for HRT 
use (never, past, current, or premenopausal at 
the time of bone lead measurement). In addi-
tion, to limit the possibility that lead released 
from bone after menopause affected bone lead 
concentrations differentially with respect to 
age at menopause, we performed a sensitivity 
analysis restricted to women whose bone lead 
was measured > 5 years after menopause. The 
5-year cut point was chosen to approximate 
the time when the most rapid menopausal 
bone loss has ended (Greendale et al. 2012; 
Recker 2011). Only 28 women went through 
menopause after bone lead measurement, too 
few to run analyses restricted to that group. 
We used SAS version 9 (SAS Institute Inc., 
Cary, NC, USA) for all these analyses. We 
used R version 3.0.2 (R Project for Statistical 
Computing, Vienna, Austria) to examine the 
smoothed, adjusted association between tibia 
lead and age at menopause with a natural 
spline. We used Akaike’s information cri-
terion to determine the optimal number of 
knots. This study was approved by the institu-
tional review board of Brigham and Women’s 
Hospital. All women gave written consent to 
participate in studies of lead exposure.
Results
The mean (± SD) age at bone lead measure-
ment was 61.1 ± 5.9 years (59.4 ± 7.1 years 
in the hypertension substudy and 62.4 ± 4.3 
years in the bone density substudy). The mean 
age at menopause was 50.8 ± 3.6 years. Of the 
434 women in our analyses, 28 were premeno-
pausal at bone lead measurement, with a mean 
of 3.5 ± 1.7 years between their bone lead 
measurement and menopause. The remaining 
women were postmenopausal at bone lead 
measurement, with a mean time between 
menopause and subsequent lead measurement 
of 11.3 ± 6.3 years. Overall the median con-
centrations of tibia, patella, and blood lead 
were 10 μg/g [interquartile range (IQR), 
4–15], 12 μg/g (IQR, 6–18), and 3 μg/dL 
(IQR, 2–4), respectively. The distributions of 
bone lead concentrations by participant charac-
teristics are shown in Table 1. As was observed 
in our previous case–control study of lead and 
hypertension in the first NHS subgroup, both 
tibia and patella lead levels were higher with 
older age, more pack-years of smoking, and 
alcohol intake (Korrick et al. 2002).
Higher tibia lead was associated with a sig-
nificantly younger age at menopause (Table 2). 
Compared with women in the lowest tertile 
of tibia lead, those in the highest tertile were 
1.21 years younger at menopause on average 
(95% CI: –2.08, –0.35; p-trend = 0.006). An 
IQR (11 μg/g) increase in tibia lead concen-
tration was associated with an age 0.89 year 
younger (95% CI: –1.52, –0.25) at meno-
pause. The analysis of trend using quintiles 
of tibia lead was also significant (p = 0.05). 
A smooth plot of the adjusted association 
between tibia lead and age at menopause sug-
gested that the inverse association flattens out 
somewhat at higher tibia levels (Figure 1), but 
this is also in the range where there were fewer 
data. Age at menopause was not associated 
with patella or blood lead (Table 2).
When age at menopause was dichoto-
mized as early (< 45 years of age) or not, 
higher tibia lead was associated with early 
menopause (Table 3). Women in the high-
est tertile of tibia lead (n = 14 cases) had 
Table 1. Lead exposure biomarkers by general characteristics (n = 434) (mean ± SD).
Characteristic na
Tibia lead 
(μg/g)
Patella lead 
(μg/g)b
Blood lead 
(μg/dL)c
Age at bone lead measure (years)
46–54 62 9.3 ± 7.3 12.8 ± 10.0 2.8 ± 2.2
55–59 100 9.3 ± 7.6 10.3 ± 8.9 2.8 ± 1.7
60–64 141 8.6 ± 9.8 12.0 ± 11.1 3.1 ± 1.9
65–69 101 12.2 ± 10.7 11.7 ± 13.3 3.0 ± 1.5
≥ 70 30 12.9 ± 12.7 16.9 ± 15.0 3.6 ± 2.9
Age at menarche (years)
< 13 188 9.4 ± 9.6 12.2 ± 11.2 3.0 ± 1.9
13 147 9.9 ± 8.9 11.1 ± 11.6 3.0 ± 2.0
> 13 99 11.3 ± 10.5 12.9 ± 11.5 2.9 ± 1.9
Oral contraception use (months)
Never user 221 10.5 ± 10.2 12.3 ± 11.5 3.2 ± 2.0
≤ 24 93 9.8 ± 9.4 12.2 ± 12.5 2.8 ± 1.7
25–60 73 8.7 ± 8.9 10.9 ± 10.7 3.0 ± 2.0
> 60 47 10.1 ± 8.0 11.7 ± 10.0 2.6 ± 1.5
Parity
Nulliparous 22 17.7 ± 14.2 15.7 ± 17.2 2.7 ± 2.2
1 21 12.6 ± 10.6 13.3 ± 10.8 3.4 ± 2.2
2 113 8.3 ± 9.7 10.8 ± 10.8 2.8 ± 1.8
3 135 8.5 ± 8.1 11.5 ± 9.4 3.1 ± 1.9
≥ 4 143 11.2 ± 9.1 12.5 ± 12.6 3.0 ± 1.9
Pack-years of cigarette smokingd
0 167 9.0 ± 8.6 10.7 ± 10.8 2.7 ± 1.6
1–4 43 8.6 ± 10.8 10.0 ± 8.7 2.7 ± 1.3
5–19 127 10.1 ± 9.9 12.9 ± 11.5 3.2 ± 2.3
20–80 97 12.3 ± 9.9 14.0 ± 13.0 3.5 ± 2.0
Alcohol consumption (g/day)d
< 1.0 117 8.5 ± 8.4 10.1 ± 9.7 2.6 ± 1.5
1.0–4.9 114 10.2 ± 9.0 11.6 ± 11.8 3.0 ± 1.7
5.0–9.9 67 8.7 ± 10.5 12.1 ± 12.2 2.8 ± 1.8
≥ 10 113 11.5 ± 10.1 13.8 ± 10.7 3.5 ± 2.3
BMId
< 20 36 10.4 ± 8.9 13.1 ± 9.6 3.4 ± 1.9
20 to < 25 302 9.9 ± 9.8 12.2 ± 10.8 3.1 ± 2.0
≥ 25 94 10.0 ± 9.4 10.8 ± 13.7 2.5 ± 1.6
HRT usee
Never 109 11.4 ± 10.4 12.2 ± 13.1 3.9 ± 2.4
Past 152 9.3 ± 10.8 11.4 ± 12.3 3.1 ± 1.6
Current 134 9.9 ± 7.6 12.2 ± 9.2 2.2 ± 1.4
Premenopausal 28 9.1 ± 8.3 13.1 ± 11.5 2.4 ± 1.7
aBecause of missing observations for alcohol consumption (n = 22), BMI (n = 2), and HRT use (n = 11), not all covariates 
have 434 observations. bn = 1 missing. cn = 6 missing. dAt time of menopause. eAt time of bone lead measurement. 
Table 2. Differencea (95% CI) in age at natural 
menopause by lead biomarker concentration 
(n = 434).
Lead biomarker n
Difference in age at 
natural menopause 
(years)
Tibia lead tertile (μg/g)
< 6.5 143 Reference
6.5–13 145 –0.80 (–1.67, 0.06)
> 13 146 –1.21 (–2.08, –0.35)
p for trend testb 0.006
Patella lead tertile (μg/g)c
< 8 134 Reference
8–15 150 –0.32 (–1.18, 0.55)
≥ 15 149 –0.00 (–0.88, 0.87)
p for trend testb 0.99
Blood lead tertile (μg/dL)d
< 3 192 Reference
3 106 0.08 (–0.80, 0.96)
> 3 130 –0.28 (–1.13, 0.56)
p for trend testb 0.54
aAdjusted for substudy group, age at bone lead measure, 
age at bone lead measure squared, year of birth, age at 
menarche, months of oral contraceptive use, parity, and 
pack-years of smoking. bCalculated using linear regres-
sion with a continuous lead biomarker term created by 
assigning each woman the median value of her lead 
biomarker tertile. cn = 1 missing. dn = 6 missing.Eum et al.
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an OR of 5.30 (95% CI: 1.42, 19.78; 
p-trend = 0.006) compared with women in 
the lowest tertile (n = 3 cases). The analysis 
of trend using quintiles of tibia lead was also 
significant (p = 0.02). For an IQR (11 μg/g) 
increase in tibia lead concentration, the OR 
for early menopause was 3.68 (95% CI: 
1.46, 9.29). As with analyses of continuous 
age at menopause, no association was seen 
for early menopause with blood or patella 
lead (Table 3).
Associations between tibia lead and age 
at menopause (see Supplemental Material, 
Table S1) and early menopause (see 
Supplemental Material, Table S2) were simi-
lar to those for the main analysis when we 
additionally adjusted for BMI and alcohol 
consumption, or for hormone replacement 
therapy, or when we restricted the analyses 
to women who were premenopausal in 1976 
(n = 401). The association between tibia lead 
and age at menopause also was similar to the 
main analysis when we restricted the model 
to women whose bone lead was measured 
> 5 years after menopause (see Supplemental 
Material, Table S1). However, we did not 
perform this sensitivity analysis for early 
menopause because of insufficient numbers of 
cases. The null association of patella lead with 
menopause was unchanged when restricted to 
women who were > 5 years after menopause 
at their bone lead measurement. No sensitivity 
analyses were performed for the remaining null 
findings using blood and patella lead measures.
Discussion
In this study of cumulative lead exposure and 
age at menopause among women with general 
environmental exposure to lead, we found a 
strong association between higher long-term 
cumulative lead exposure—as measured by 
lead in the tibia—and younger age at natural 
menopause. Specifically, women in the high-
est tertile of tibia lead had five times greater 
risk of early menopause and experienced 
menopause > 1 year earlier than women in 
the lowest tibia lead tertile. From a public 
health perspective, it is important that these 
findings were among non  occupationally 
exposed women with low lead levels (the aver-
age blood lead concentration was 3 μg/dL) 
comparable to measures in older adult women 
from the general U.S. population (Campbell 
and Auinger 2007).
Nonsurgical menopause is triggered by 
the decline in the number and function of 
ovarian follicles during the programmed pro-
cess of ovarian follicle atresia (Broekmans 
et al. 2009). From at least 300,000 to 
400,000 at menarche, the estimated number 
of primordial follicles falls below 1,000 at the 
time of menopause, and oocyte quality also 
diminishes (Faddy et al. 1992). The HPG axis 
may also contribute to the age-related decline 
in reproductive function, as a decline in nega-
tive feedback from the ovaries alters HPG 
signaling (Downs and Wise 2009).
Although the mechanism whereby gen-
eral environmental lead exposure might lead 
to earlier menopause is uncertain, results of 
experimental animal models, including studies 
of nonhuman primates, and in vitro studies 
suggest that lead may affect the female repro-
ductive system in several ways that could con-
tribute to earlier menopause [Doumouchtsis 
et al. 2009; U.S. Environmental Protection 
Agency (EPA) 2012]. For example, in an 
in vitro study of human ovarian granulosa cells 
collected from women undergoing in vitro fer-
tilization, cells grown on media that contained 
lead acetate accumulated lead, which was 
accompanied by lower levels of p450 aro-
matase messenger RNA, cytochrome p450 
aromatase, and estrogen receptor β proteins 
than untreated cells (Taupeau et al. 2003). 
Although the applicability of these in vitro 
findings to the in vivo setting is uncertain, 
aromatase is required for the transformation 
of androgen to estradiol, and estrogen recep-
tor β mediates estrogen effects in granulosa 
cells, actions that are essential for follicular 
growth and maturation, oogenesis, ovula-
tion, and normal luteal functions in vivo 
(Ryan 1982). In addition to direct damage 
of ovarian cells and ovarian atrophy at high 
lead levels (Taupeau et al. 2001; Vermande-
Van Eck and Meigs 1960), lead also dis-
rupts endocrine function at multiple points 
along the HPG axis including, for example, 
altered pituitary gonadotropin production in 
response to gonadotropin-releasing hormone 
(Doumouchtsis et al. 2009; U.S. EPA 2012),
Evidence from epidemiologic studies 
supports the possibility that lead exposures 
typical of the general population have repro-
ductive effects that could impact menopause. 
For example, in the National Health And 
Nutrition Examination Survey (NHANES), 
lead levels were associated with altered serum 
follicle-stimulating hormone (FSH) concentra-
tions among premenopausal women (Kreig 
2007; Krieg and Feng 2011); however, in 
another much smaller sample, associations 
between blood lead and FSH were not seen 
(Jackson et al. 2011; Pollack et al. 2011). 
Among 52 occupationally exposed lead battery 
plant and capacitor factory workers, female 
lead-exposed workers showed a significantly 
higher prevalence of polymenorrhea and 
prolonged and abnormal menstruation than 
did a control group of 62 women who were 
randomly sampled workers in administrative 
or non-lead-production departments (Tang 
and Zhu 2003). Several epidemiological stud-
ies have also found associations between lead 
exposure and reduced fertility in women, as 
well as later menarche and pubertal develop-
ment (U.S. EPA 2012), although the relevance 
of these end points to menopause is less clear.
Whether lead exposure is associated with 
age at menopause has been explored in only 
one occupational study (Popovic et al. 2005) 
and one cross-sectional study of the general 
population (Mendola et al. 2013). Among 
a highly lead exposed group of 108 former 
smelter employees (Popovic et al. 2005), the 
mean age at menopause was significantly 
(p = 0.001) younger than among a group of 
99 community controls with no known occu-
pational lead exposures. However, the compa-
ny’s preferential hiring of women for smelter 
jobs who were unable to have children creates 
a selection bias—one that likely explains the 
early age at natural menopause, 43.7 years 
Table 3. ORa (95% CI) for early menopause by lead 
biomarker concentration (n = 434).
Lead biomarker
Case/
control
Early menopause 
(< 45 years)
Tibia lead tertile (μg/g)
< 6.5 3/140 Reference
6.5–13 6/139 1.86 (0.44, 7.95)
> 13 14/132 5.30 (1.42, 19.78)
p for trend testb 0.006
Patella lead tertile (μg/g)c
< 8 7/127 Reference
8–15 11/139 1.24 (0.45, 3.42)
≥ 15 5/144 0.52 (0.15, 1.78)
p for trend testb 0.30
Blood lead tertile (μg/dL)d
< 3 9/183 Reference
3 7/99 1.43 (0.50, 4.12)
> 3 7/123 1.22 (0.42, 3.58)
p for trend testb 0.68
aAdjusted for substudy group, age at bone lead measure, 
age at bone lead measure squared, year of birth, age at 
menarche, months of oral contraceptive use, parity, and 
pack-years of smoking. bCalculated using linear regres-
sion with a continuous lead biomarker term created by 
assigning each woman the median value of her lead 
biomarker tertile. cn = 1 missing. dn = 6 missing.
Figure 1. Smoothed (natural spline, 3 knots) 
association between tibia lead concentration and 
age at menopause, adjusted for substudy group, 
age at bone lead measurement, age at bone 
lead measure  ment squared, year of birth, age at 
menarche, months of oral contraceptive use, parity, 
and pack-years of smoking. The stippled lines indi-
cate the 95% CIs. Short vertical lines on the x-axis 
represent individual women in the study.
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on average among the lead workers—that 
limits the validity of these results. Exposures 
in the second study, a cross-sectional analy-
sis of NHANES data, are applicable to the 
general population, but the directionality of 
the observed association of higher blood lead 
(2–22 μg/dL) with increased odds of natural 
menopause among 45- to 55-year-old women 
is uncertain (Mendola et al. 2013). Although 
this association remained after adjustment for 
markers of bone turnover or bone density, 
in a cross-sectional analysis, such measures 
cannot account for previous postmenopausal 
releases of lead from bone to blood.
The major strengths of this study 
include having a large group of non  occupa-
tionally exposed women with bone lead 
measurements—a cumulative lead exposure 
marker—and extensive additional covariate 
data. One of the study’s limitations is that 
bone lead biomarkers were measured mostly 
after menopause, thus reverse causation is 
possible (that is, age at menopause affects 
lead levels, as opposed to lead affecting age 
at menopause). Because our bone lead mea-
sures were made over a relatively short time 
interval, women with an earlier age at meno-
pause had more years since menopause at the 
time of their bone lead measurements than 
women with later menopause. Although the 
effect of menopause on bone lead concentra-
tion has not been examined empirically, if 
menopause-related bone loss causes relatively 
higher bone lead concentration with more 
time since menopause, this could account for 
our findings. However, this seems unlikely 
at face value, but in any case menopause-
related bone loss occurs primarily in trabecular 
(patella) bone rather than cortical (tibia) bone 
(Riggs et al. 1982). Therefore, reverse causa-
tion would be expected to be most apparent 
for patella lead, but we found associations 
with tibia lead not patella lead. In addition, 
the most rapid menopause-related bone loss 
occurs in the first 5 years after menopause, yet 
we still saw associations among women who 
were > 5 years after menopause at the time 
of bone lead measurement. These findings 
suggest that possible menopause-associated 
changes in bone lead are unlikely to explain 
the observed associations with tibia lead. 
Nonetheless, only a prospective study with 
bone lead measured before menopause would 
answer this question with certainty.
In our study, blood and patella lead likely 
predominantly reflect postmenopausal lead 
exposure given their respective half-lives of 
months to years, and the fact that blood col-
lection and bone lead measurements were 
done well after most study women were post-
menopausal. Thus, a possible explanation 
for the null blood and patella results is that 
effects of lead on age at menopause are driven 
by long-term, premenopausal lead exposures 
that are reflected better by tibia lead because 
of its longer half-life (on the order of decades) 
(Wilker et al. 2011).
In conclusion, this study on the association 
between bone lead, a measure of long-term 
lead exposure, and age at menopause suggests 
that cumulative exposure to lead in a non-
occupationally exposed group is associated 
with an earlier age at menopause. Given the 
relation between earlier menopause and many 
subsequent health problems, these results sug-
gest a pathway by which lead may contrib-
ute to the burden of chronic disease in older 
women. The success in reducing external lead 
exposures in the United States may mean that 
women entering menopause today are at less 
risk of lead-associated earlier age at menopause 
than we observed, but the possibility remains 
that further reductions in lead levels could still 
improve the health of women as they age.
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